Brokerages Set Septerna, Inc. (NASDAQ:SEPN) Price Target at $33.83

Shares of Septerna, Inc. (NASDAQ:SEPN) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $33.8333.

SEPN has been the subject of several analyst reports. Wells Fargo & Company upgraded Septerna from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $18.00 to $28.00 in a research note on Friday, November 14th. Zacks Research cut Septerna from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Truist Financial started coverage on Septerna in a research note on Monday, December 15th. They issued a “buy” rating and a $34.00 price objective on the stock. Wall Street Zen downgraded Septerna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd.

Insider Activity

In other news, SVP Daniel D. Long sold 3,501 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the sale, the senior vice president directly owned 92,911 shares in the company, valued at $1,677,972.66. This trade represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Septerna

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Septerna by 7.4% during the third quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock valued at $28,568,000 after acquiring an additional 104,394 shares during the period. Avoro Capital Advisors LLC raised its stake in Septerna by 8.1% during the 3rd quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock valued at $25,158,000 after purchasing an additional 100,000 shares during the period. ADAR1 Capital Management LLC lifted its holdings in Septerna by 38.9% in the 3rd quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock worth $22,130,000 after purchasing an additional 329,264 shares in the last quarter. VR Adviser LLC lifted its holdings in Septerna by 13.0% in the 3rd quarter. VR Adviser LLC now owns 610,808 shares of the company’s stock worth $11,489,000 after purchasing an additional 70,355 shares in the last quarter. Finally, Woodline Partners LP boosted its stake in Septerna by 94.2% in the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock worth $3,373,000 after purchasing an additional 282,585 shares during the period.

Septerna Stock Down 2.0%

Shares of NASDAQ:SEPN opened at $24.44 on Tuesday. The stock has a market capitalization of $1.09 billion, a PE ratio of -16.19 and a beta of 3.85. The firm’s 50 day moving average price is $26.57 and its 200-day moving average price is $20.55. Septerna has a twelve month low of $4.17 and a twelve month high of $30.50.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. The business had revenue of $21.50 million for the quarter, compared to analysts’ expectations of $24.50 million. Analysts expect that Septerna will post -7.11 earnings per share for the current fiscal year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.